Short Interest to Follow: Is Spectrum Pharmaceuticals Incorporated (NASDAQ:SPPI) a Buy? The Stock Reported more Sellers

November 16, 2016 - By Pete Kolinski   ·   0 Comments

Short Interest to Follow: Is Spectrum Pharmaceuticals Incorporated (NASDAQ:SPPI) a Buy? The Stock Reported more Sellers

The stock of Spectrum Pharmaceuticals Incorporated (NASDAQ:SPPI) registered an increase of 11.59% in short interest. SPPI’s total short interest was 8.23 million shares in November as published by FINRA. Its up 11.59% from 7.38M shares, reported previously. With 1.02M shares average volume, it will take short sellers 8 days to cover their SPPI’s short positions. The short interest to Spectrum Pharmaceuticals Incorporated’s float is 14.27%. About 235,519 shares traded hands. Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI) has declined 38.55% since April 14, 2016 and is downtrending. It has underperformed by 43.23% the S&P500.

Spectrum Pharmaceuticals, Inc. is a biotechnology company. The company has a market cap of $324.58 million. The Firm operates through developing and commercializing oncology and hematology drug products segment. It currently has negative earnings. It has approximately six approved oncology/hematology products that target different types of non-Hodgkin’s lymphoma , metastatic colorectal cancer, acute lymphoblastic leukemia (ALL) and multiple myeloma (MM).

Insitutional Activity: The institutional sentiment increased to 3.84 in Q2 2016. Its up 2.68, from 1.16 in 2016Q1. The ratio increased, as 7 funds sold all Spectrum Pharmaceuticals, Inc. shares owned while 18 reduced positions. 34 funds bought stakes while 62 increased positions. They now own 106.93 million shares or 131.39% more from 46.21 million shares in 2016Q1.
Blackrock Group Limited last reported 116,590 shares in the company. State Street Corporation holds 0% or 1.94M shares in its portfolio. Barclays Public Limited Company last reported 0.01% of its portfolio in the stock. Moreover, Goldman Sachs Group has 0% invested in Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI) for 1.57 million shares. Parametric Associate Ltd Com has 0% invested in the company for 164,703 shares. Ladenburg Thalmann Financial has 0% invested in the company for 9,364 shares. Limited Liability last reported 0.01% of its portfolio in the stock. Quantitative Invest Mgmt Limited Liability Co holds 49,700 shares or 0.02% of its portfolio. Wells Fargo Co Mn holds 578,205 shares or 0% of its portfolio. Blackrock Institutional Tru Na holds 1.89 million shares or 0% of its portfolio. Royal Bank Of Canada accumulated 970,332 shares or 0% of the stock. Teachers Incorporated holds 1.02 million shares or 0.01% of its portfolio. Teachers Retirement Of The State Of Kentucky reported 13,500 shares or 0% of all its holdings. Teacher Retirement Systems Of Texas last reported 9,513 shares in the company. Springbok Capital Mgmt Ltd Liability accumulated 0% or 5,374 shares.

SPPI Company Profile

Spectrum Pharmaceuticals, Inc., incorporated on November, 18, 2002, is a biotechnology company. The Firm operates through developing and commercializing oncology and hematology drug products segment. The Firm has approximately six approved oncology/hematology products that target different types of non-Hodgkin’s lymphoma (NHL), metastatic colorectal cancer, acute lymphoblastic leukemia (ALL) and multiple myeloma (MM). It also has two drugs in late-stage development: SPI-2012, which is being developed for chemotherapy-induced neutropenia in patients with breast cancer, and EOQUIN, which is being developed for immediate intravesical instillation post-transurethral resection of bladder tumors in patients with non-muscle invasive bladder cancer. It has a product portfolio consisting of both commercial-stage and development-stage products that address various cancer types. The Company’s commercialized products include FUSILEV, FOLOTYN, ZEVALIN, MARQIBO, BELEODAQ and EVOMELA. The Company’s other products include SPI-2012, POZIOTINIB and EOQUIN.

Another recent and important Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI) news was published by Businesswire.com which published an article titled: “IMPORTANT SHAREHOLDER ALERT: Lundin Law PC Announces Securities Class Action …” on November 08, 2016.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By Pete Kolinski


Readers Comments (0)





Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


Recent Market News

>